The court website has shown an increase in Risperdal lawsuits with the addition of 534 cases to the Pennsylvania Risperdal Mass tort. With this, 6082 is the total count of Risperdal cases as compared to the June count of 5548 cases.
Two co-ordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
Prescribed mainly for severe psychiatric conditions, Risperdal came under the scanner when it showed side-effects in males due to the increased prolactin levels that led to sexual dysfunction, an inability to create sperm, and breast enlargement. Civil and criminal allegations involving the marketing of off-label and unapproved usage of Risperdal cost J&J $2.2 billion as settlement charges in 2013. Since 2012, J&J has settled numerous cases and has also lost to plaintiffs in trial proceedings.